{Reference Type}: Journal Article
{Title}: Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations.
{Author}: Karady J;Lu MT;Bergström G;Mayrhofer T;Taron J;Foldyna B;Paradis K;McCallum S;Aberg JA;Currier JS;Fitch KV;Fulda ES;Bloomfield GS;Overton ET;Lind L;Östgren CJ;Elvstam O;Söderberg S;Jernberg T;Pepe R;Dubé MP;Mushatt D;Fichtenbaum CJ;Malvestutto C;Zanni MV;Hoffmann U;Ribaudo H;Grinspoon SK;Douglas PS;
{Journal}: JACC Adv
{Volume}: 3
{Issue}: 6
{Year}: 2024 Jun
暂无{DOI}: 10.1016/j.jacadv.2024.100968
{Abstract}: <B>UNASSIGNED: </B>People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification.<BR><B>UNASSIGNED: </B>The purpose of this study was to determine coronary plaque burden/phenotype in PWH vs PwoH.<BR><B>UNASSIGNED: </B>Nonstatin using participants from 3 contemporary populations without known coronary plaques with coronary CT were compared: the REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) studying PWH without cardiovascular symptoms at low-to-moderate risk (n = 755); the SCAPIS (Swedish Cardiopulmonary Bioimage Study) of asymptomatic community PwoH at low-to-intermediate cardiovascular risk (n = 23,558); and the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) of stable chest pain PwoH (n = 2,291). The coronary plaque prevalence on coronary CT was compared, and comparisons were stratified by 10-year atherosclerotic cardiovascular disease (ASCVD) risk, age, and coronary artery calcium (CAC) presence.<BR><B>UNASSIGNED: </B>Compared to SCAPIS and PROMISE PwoH, REPRIEVE PWH were younger (50.8 ± 5.8 vs 57.3 ± 4.3 and 60.0 ± 8.0 years; P < 0.001) and had lower ASCVD risk (5.0% ± 3.2% vs 6.0% ± 5.3% and 13.5% ± 11.0%; P < 0.001). More PWH had plaque compared to the asymptomatic cohort (48.5% vs 40.3%; P < 0.001). When stratified by ASCVD risk, PWH had more plaque compared to SCAPIS and a similar prevalence of plaque compared to PROMISE. CAC = 0 was more prevalent in PWH (REPRIEVE 65.2%; SCAPIS 61.6%; PROMISE 49.6%); among CAC = 0, plaque was more prevalent in PWH compared to the PwoH cohorts (REPRIEVE 20.8%; SCAPIS 5.4%; PROMISE 12.3%, P < 0.001).<BR><B>UNASSIGNED: </B>Asymptomatic PWH in REPRIEVE had more plaque than asymptomatic PwoH in SCAPIS but had similar prevalence to a higher-risk stable chest pain cohort in PROMISE. In PWH, CAC = 0 does not reliably exclude plaque.